Leiomyosarcoma (LMS)

Request an Appointment

Survival rates

Survival rates are estimates based on groups of people with the same type of cancer. Survival rates are based on people treated in previous years and may not reflect newer treatments. They can give a general idea of prognosis, which is sometimes referred to as outlook. But they can't predict what will happen to one person.

Survival varies depending on where the cancer starts and how far it has spread. A tumor that is small and has not spread to other areas tends to have a better prognosis. The type of treatment also can affect outcome.

Leiomyosarcoma can come back after treatment. This is called a recurrence.

Talk with your healthcare team what the prognosis might be in your situation.

What affects survival

Factors that may affect the outlook for leiomyosarcoma include:

  • Where the cancer started.
  • The stage of the cancer and whether it has spread.
  • The tumor grade, which gives clues about how quickly the cancer may grow and spread.
  • Whether surgery can remove all visible cancer.
  • Your overall health.
  • How the cancer responds to treatment.
Request an appointment
StagesDoctors & departments
Aug. 29, 2026

Living with leiomyosarcoma (LMS)?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

citizendeveloper
FS-DFSP (Fibrosarcomatous dermatofibrosarcoma): Anyone else?

54 Replies Thu, Aug 27, 2026

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

1094 Replies Wed, Aug 26, 2026

lessjudd1976
What treatments did you have for angiosarcoma?

9 Replies Sun, Aug 23, 2026

See more discussions
  1. Leiomyosarcoma. National Cancer Institute. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/leiomyosarcoma. Accessed Aug. 17, 2026.
  2. Haddox CL, et al. Leiomyosarcoma therapeutic approaches and future directions. Hematology/Oncology Clinics of North America. 2025; doi:10.1016/j.hoc.2025.04.007.
  3. Soft tissue sarcoma treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq. Accessed Aug. 17, 2026.
  4. Pautier P, et al. Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2403394.
  5. Uterine sarcoma treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/uterine/hp/uterine-sarcoma-treatment-pdq. Accessed Aug. 17, 2026.
  6. Raffone A, et al. Diagnostic accuracy of MRI in the differential diagnosis between uterine leiomyomas and sarcomas: A systematic review and meta-analysis. International Journal of Gynecology & Obstetrics. 2024; doi:10.1002/ijgo.15136.
  7. Zapardiel I, et al. Prognostic factors in patients with uterine sarcoma: The SARCUT study. International Journal of Gynecological Cancer. 2023; doi:10.1136/ijgc-2022-004204.
  8. Pearce H, et al. Tumor genomics, metastatic patterns, and prognosis in leiomyosarcoma: A single-center retrospective cohort study. Cancers. 2025; doi:10.3390/cancers17213544.
  9. Øines MN, et al. Leiomyosarcoma of the abdomen and retroperitoneum: A systematic review. Frontiers in Surgery. 2024; doi:10.3389/fsurg.2024.1375483.
  10. Li F, et al. A world-wide systematic review of the primary leiomyosarcoma of inferior vena cava. Asian Journal of Surgery. 2023; doi:10.1016/j.asjsur.2023.09.018.
  11. Gingrich A, et al. Clinical variables influencing outcomes in patients with atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): Single-institution study of 95 surgical patients. Annals of Surgical Oncology. 2024; doi:10.1245/s10434-024-15528-x.
  12. Bao Y, et al. Analysis of demographics and treatment outcomes for gastrointestinal leiomyosarcoma based on the SEER database. Scientific Reports. 2025; doi:10.1038/s41598-025-91758-7.
  13. Votrient (prescribing information). Novartis Pharmaceuticals; 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7. Accessed Aug. 17, 2026.
  14. Testing the addition of an anti-cancer drug, abemaciclib, to the usual chemotherapy treatment (gemcitabine) for soft tissue sarcoma. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06498648. Accessed Aug. 17, 2026.
  15. Understanding cancer prognosis. National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis. Accessed Aug. 17, 2026.
  16. Medical review (expert opinion). Mayo Clinic. Aug. 25, 2025.

Related

Products & Services

Leiomyosarcoma (LMS)